BRPI0411904A - formulações inaláveis para o tratamento de hipertensão pulmonar e processos para utilização das mesmas - Google Patents

formulações inaláveis para o tratamento de hipertensão pulmonar e processos para utilização das mesmas

Info

Publication number
BRPI0411904A
BRPI0411904A BRPI0411904-5A BRPI0411904A BRPI0411904A BR PI0411904 A BRPI0411904 A BR PI0411904A BR PI0411904 A BRPI0411904 A BR PI0411904A BR PI0411904 A BRPI0411904 A BR PI0411904A
Authority
BR
Brazil
Prior art keywords
pulmonary hypertension
treatment
present
processes
blocker
Prior art date
Application number
BRPI0411904-5A
Other languages
English (en)
Inventor
Imtiaz Chaudry
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0411904A publication Critical patent/BRPI0411904A/pt
Publication of BRPI0411904B1 publication Critical patent/BRPI0411904B1/pt
Publication of BRPI0411904B8 publication Critical patent/BRPI0411904B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES INALáVEIS PARA O TRATAMENTO DE HIPERTENSãO PULMONAR E PROCESSOS PARA UTILIZAçãO DAS MESMAS". A presente invenção refere-se a uma formulação inalável para o tratamento de hipertensão pulmonar em um mamífero (por exemplo, seres humanos), em que a formulação compreende pelo menos um agente redutor de hipertensão, incluindo porém não limitado a um inibidor de enzima conversor de angiotensina, um bloqueador receptor de angiotensina, um beta-bloqueador, um bloqueador de canal de cálcio ou um vasodilatador ou qualquer combinação dos mesmos. As formulações da presente invenção podem ser uma solução ou uma suspensão e de preferência são adequadas para a administração por nebulização. A presente invenção também é dirigida a um processo e a um kit para o tratamento de um mamífero que sofra de hipertensão pulmonar.
BRPI0411904A 2003-06-27 2004-06-18 formulações inaláveis para o tratamento de hipertensão pulmonar BRPI0411904B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/609,233 US20040265238A1 (en) 2003-06-27 2003-06-27 Inhalable formulations for treating pulmonary hypertension and methods of using same
US10/609,233 2003-06-27
PCT/EP2004/006629 WO2005000270A2 (en) 2003-06-27 2004-06-18 Inhalable formulations for treating pulmonary hypertension and methods of using same

Publications (3)

Publication Number Publication Date
BRPI0411904A true BRPI0411904A (pt) 2006-08-08
BRPI0411904B1 BRPI0411904B1 (pt) 2020-11-03
BRPI0411904B8 BRPI0411904B8 (pt) 2021-05-25

Family

ID=33540807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411904A BRPI0411904B8 (pt) 2003-06-27 2004-06-18 formulações inaláveis para o tratamento de hipertensão pulmonar

Country Status (16)

Country Link
US (3) US20040265238A1 (pt)
EP (1) EP1638525B1 (pt)
JP (3) JP5571867B2 (pt)
KR (3) KR101824298B1 (pt)
CN (1) CN1822817B (pt)
AT (1) ATE548025T1 (pt)
AU (2) AU2004251014B8 (pt)
BR (1) BRPI0411904B8 (pt)
CA (1) CA2530632C (pt)
ES (1) ES2384384T3 (pt)
HK (1) HK1093017A1 (pt)
MX (1) MXPA05013539A (pt)
PL (1) PL1638525T3 (pt)
RU (2) RU2491072C2 (pt)
WO (1) WO2005000270A2 (pt)
ZA (1) ZA200600773B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541454A (en) * 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP4702054B2 (ja) 2003-05-09 2011-06-15 東レ株式会社 増強剤
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CA2549724C (en) * 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
JP2008501031A (ja) * 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド ムスカリン受容体のモジュレーター
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
JP2009511594A (ja) * 2005-10-14 2009-03-19 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド ニモジピンの液体製薬学的組成物
CN101495122B (zh) * 2006-05-15 2011-10-05 联合治疗公司 使用定量吸入器给予曲前列尼
CA2653744C (en) * 2006-05-26 2018-01-16 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
WO2008002929A2 (en) * 2006-06-26 2008-01-03 Inverseon, Inc. Heterologous cross-sensitization for improved agonist activity
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2008149201A2 (en) * 2007-06-06 2008-12-11 Emcure Pharmaceuticals Limited Stable pharmaceutical composition
MX2010000927A (es) * 2007-07-24 2010-05-19 Viridis Biopharma Pvt Ltd Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos.
EP2237788A4 (en) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
CA2737350A1 (en) * 2008-09-25 2010-04-01 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
JP5649645B2 (ja) * 2009-05-07 2015-01-07 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンアナログの固形製剤
CN101891596B (zh) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 一种化合物及其制备方法和用途
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2461812B1 (en) * 2009-08-07 2014-01-01 SciPharm SàRL Composition for the treatment of cystic fibrosis
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
EA022849B1 (ru) 2010-10-12 2016-03-31 Дзе Медсинз Компани Эмульсионные композиции клевидипина, содержащие противомикробные агенты
CN102580090A (zh) * 2011-01-06 2012-07-18 北京水圣木科技有限责任公司 一种用于治疗高血压的颗粒剂
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
RU2593016C2 (ru) * 2014-12-15 2016-07-27 Федеральное государственное бюджетное учреждение науки Институт теоретической и прикладной механики им. С.А. Христиановича Сибирского отделения Российской академии наук (ИТПМ СО РАН) Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
US11241379B2 (en) 2015-12-01 2022-02-08 Sun Pharmaceutical Industries Limited Parenteral dosage form of diltiazem
US20170216538A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry Powder Inhaler
HU231031B1 (hu) * 2016-03-23 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására
WO2018016596A1 (ja) * 2016-07-20 2018-01-25 国立大学法人東北大学 ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
EP4135707A1 (en) 2020-04-17 2023-02-22 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
WO2023206444A1 (zh) * 2022-04-29 2023-11-02 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂
CN114652704A (zh) * 2022-04-29 2022-06-24 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023244973A1 (en) 2022-06-13 2023-12-21 Epicentrx, Inc. Compositions and methods for reducing adverse side effects in cancer treatment
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
GB1114313A (en) * 1964-11-19 1968-05-22 Wyeth John & Brother Ltd Pharmaceutical compositions
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
USD275732S (en) 1982-05-21 1984-10-02 Dey Laboratories, Inc. Liquid dispensing container
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
USD289609S (en) 1984-11-29 1987-05-05 Dey Laboratories, Inc. Liquid dispensing container
USD296869S (en) 1985-09-18 1988-07-26 Dey Laboratories, Inc. Liquid dispensing container
EP0302595B1 (en) * 1987-07-07 1994-02-02 Beecham Group Plc Pinacidil for treatment of pulmonary hypertension or right heart failure
USD317715S (en) 1989-10-10 1991-06-25 Dey Laboratories, Inc. Liquid dispensing container
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
HU227346B1 (en) 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
DE560928T1 (de) * 1990-12-05 1994-09-22 Gen Hospital Corp Vorrichtung zum behandeln einer lungengefässverengung und von asthma.
GB9118830D0 (en) * 1991-09-03 1991-10-16 Minnesota Mining & Mfg Medical aerosol formulations
DE4215317C2 (de) 1992-05-09 1994-04-21 Ver Glaswerke Gmbh Vorrichtung zum Beschichten einer Oberfläche einer Glasscheibe
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
US20020132787A1 (en) * 1993-04-07 2002-09-19 Mohammed Eljamal Compositions and methods for nucleic acid delivery to the lung
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
JPH0753358A (ja) * 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
DE4435422A1 (de) 1994-10-04 1996-04-18 Basf Ag Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
GB9601202D0 (en) 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
EP0971729B1 (en) * 1997-03-20 2002-07-03 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
ATE271028T1 (de) * 1997-04-04 2004-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
RU2161483C2 (ru) 1998-02-04 2001-01-10 Мурина Марина Алексеевна Средство для угнетения активности тромбоцитов
AU4841799A (en) * 1998-06-29 2000-01-17 Nastech Pharmaceutical Company, Inc Methods and pharmaceutical formulations for preventing and treating motion sickness
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6121300A (en) 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
CZ20011581A3 (cs) 1998-11-12 2001-12-12 Frank G. Pilkiewicz Systém pro podávání bioaktivní sloučeniny inhalací
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
CA2317999C (en) * 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
US6174906B1 (en) * 1999-10-01 2001-01-16 Smithkline Beecham Corporation Endothelin receptor antagonists
PE20010720A1 (es) * 1999-12-11 2001-07-26 Glaxo Group Ltd Distribuidor de medicamento
US20010031738A1 (en) * 2000-01-19 2001-10-18 Schwarz Margaret A. Methods and pharmaceutical formulations for the treatment of pulmonary hypertension and methods for screening compounds useful in the treatment of pulmonary hypertension
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2001054677A2 (en) 2000-01-26 2001-08-02 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
EP1292314A2 (en) * 2000-05-23 2003-03-19 The Trustees of Columbia University in the City of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
GB0014883D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20020142970A1 (en) 2000-10-10 2002-10-03 Vaughan Douglas E. Method for treating or preventing cardiovascular disease via administration of an ace inhibitor
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
JP2004512377A (ja) 2000-10-31 2004-04-22 デビオファーム・ソシエテ・アノニム ＥＰＩ−ｈＮＥタンパク質の懸濁液、その調製方法、それから由来する乾燥パウダーエアゾール、前記懸濁液またはエアゾールを含む製薬組成物、及びそれらの使用
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US20020090388A1 (en) 2000-12-01 2002-07-11 Humes H. David Intravascular drug delivery device and use therefor
US20040048905A1 (en) * 2000-12-18 2004-03-11 Daley William Lionel Therapeutic combination of amlodipine and benazepril
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
WO2003015747A1 (en) 2001-08-13 2003-02-27 Genomed, Llc Method to treat pulmonary hypoplasia in the newborn
EP1429829B1 (en) 2001-09-05 2013-11-27 Geno LLC Nitric oxide generation
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070117861A1 (en) * 2003-11-12 2007-05-24 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
US20110207555A1 (en) * 2010-02-24 2011-08-25 Bridgestone Sports Co., Ltd. Multiple-piece golf ball

Also Published As

Publication number Publication date
JP2014240443A (ja) 2014-12-25
AU2004251014B8 (en) 2011-02-10
CA2530632C (en) 2012-03-06
HK1093017A1 (en) 2007-02-23
CN1822817A (zh) 2006-08-23
BRPI0411904B8 (pt) 2021-05-25
RU2006102206A (ru) 2006-08-27
JP6141811B2 (ja) 2017-06-07
KR20140141728A (ko) 2014-12-10
KR101824298B1 (ko) 2018-01-31
WO2005000270A2 (en) 2005-01-06
US20040265238A1 (en) 2004-12-30
KR20060026070A (ko) 2006-03-22
EP1638525B1 (en) 2012-03-07
ATE548025T1 (de) 2012-03-15
AU2004251014A1 (en) 2005-01-06
RU2491072C2 (ru) 2013-08-27
ZA200600773B (en) 2007-05-30
RU2010152753A (ru) 2012-06-27
ES2384384T3 (es) 2012-07-04
JP5571867B2 (ja) 2014-08-13
AU2011200464A1 (en) 2011-02-24
MXPA05013539A (es) 2006-03-09
EP1638525A2 (en) 2006-03-29
CN1822817B (zh) 2012-10-10
US9498437B2 (en) 2016-11-22
WO2005000270A3 (en) 2005-05-12
KR20120068052A (ko) 2012-06-26
CA2530632A1 (en) 2005-01-06
PL1638525T3 (pl) 2012-10-31
JP5981109B2 (ja) 2016-08-31
JP2007519604A (ja) 2007-07-19
AU2004251014B2 (en) 2010-11-25
US20060104913A1 (en) 2006-05-18
US20110265786A1 (en) 2011-11-03
JP2012001549A (ja) 2012-01-05
BRPI0411904B1 (pt) 2020-11-03
AU2011200464B2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
BRPI0411904A (pt) formulações inaláveis para o tratamento de hipertensão pulmonar e processos para utilização das mesmas
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
PL377855A1 (pl) Preparaty i sposoby leczenia zapalenia zatok przynosowych
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2006052899A3 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
ES2194057T3 (es) Inhibidor de proteasa de leucocitos de secrecion (slpi) como inhibidor de triptasa.
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
ATE457177T1 (de) Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
WO2005060960A3 (en) Use of histamine to treat bone disease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/12; A61P 11/00

Ipc: A61K 9/12 (2011.01), A61P 11/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: MYLAN, INC. (US)

B25A Requested transfer of rights approved

Owner name: MYLAN SPECIALTY, L.P. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF